13 recruiting. 13 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 13 |
| Phase 1 | 2 | Recruiting 2 |
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B GST-HG141, GST-HG131, GST-HG141 Placebo - Chronic Hepatitis B | Phase 2 | Recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 80 | 2026-07-10 | 2026-07-17 |
| A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B AHB-137, Placebo - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 320 | 2026-06-05 | 2026-07-29 |
| A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) AHB-137, NA therapy - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 200 | 2025-09-04 | 2026-08-05 |
| TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac), TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac) - Chronic Hepatitis B | Phase 1 / Phase 2 | Recruiting | Michael Hoelscher | 81 | 2025-06-12 | 2026-06-11 |
| A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs AHB-137, Peg-IFN, Hepatitis B Vaccine - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 200 | 2025-06-08 | 2026-07-29 |
| Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B Imdusiran (AB-729) - Chronic Hepatitis B | Phase 2 | Recruiting | University of Maryland, Baltimore | 10 | 2024-07-25 | 2025-09-11 |
| A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B HRS-5635 Injection, HRS-5635 Injection (low dose) and Peg-IFN-α, HRS-5635 Injection (high dose) and Peg-IFN-α - Chronic Hepatitis B | Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 369 | 2024-06-06 | 2025-11-17 |
| A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B GST-HG131, Placebo to match GST-HG131 - Chronic Hepatitis B | Phase 2 | Recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 45 | 2023-12-26 | 2025-03-05 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B) Anti-PD-1 antibody, NAs, Peg-IFNα - Chronic Hepatitis b, Anti-PD-1 Antibody | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2023-10-10 | 2026-09-04 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B) anti-PD-1/anti-PD-L1 antibody, NAs, PEG-IFNα - Chronic Hepatitis B, Anti-PD-1 Antibody | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 1200 | 2023-10-10 | 2026-09-28 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A) Sintilimab/Envafolimab, ETV/TDF/TAF - Chronic Hepatitis B | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 1200 | 2023-10-10 | 2026-10-01 |
| A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A) Anti-PD-1 antibody, NAs - Chronic Hepatitis b, Anti-PD-1 Antibody | Phase 2 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2023-10-10 | 2026-09-22 |
| From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients Terbinafine, Placebo, Tenofovir - Chronic Hepatitis b | Phase 1 / Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 36 | 2022-04-13 | 2025-02-07 |
Hepatitis B, Chronic (13) · Hepatitis B (1)
Blood-Borne Infections (13) · Chronic Disease (13) · Communicable Diseases (13) · DNA Virus Infections (13) · Digestive System Diseases (13) · Disease Attributes (13) · Hepadnaviridae Infections (13) · Hepatitis (13) · Hepatitis, Chronic (13) · Hepatitis, Viral, Human (13) · Infections (13) · Liver Diseases (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Virus Diseases (13)
nas (3) · GST-HG131 (2) · spartalizumab (2) · Hepatitis B Vaccines (1) · Tenofovir (1) · Terbinafine (1) · envafolimab (1) · sintilimab (1)
The Second Affiliated Hospital of Chongqing Medical University (4) · Ausper Biopharma Co., Ltd. (3) · Fujian Akeylink Biotechnology Co., Ltd. (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Michael Hoelscher (1) · University of Maryland, Baltimore (1)
China (10) · Germany (1) · Netherlands (1) · United States (1)
Hong Ren, MM (4) · Junqi Niu (1) · Michael Hoelscher, Prof. Dr. med. (1) · Peng Hu (1) · Yanhua Ding (1) · Yunqing Qiu (1)